(Q37345925)

19 August 2017

1 reference

title

Mesalamine with MMX technology for the treatment of ulcerative colitis (English)

1 reference

19 August 2017

3

Gary R Lichtenstein

1 reference

19 August 2017

1

Stefan Schreiber

1 reference

19 August 2017

2

Michael A Kamm

1 reference

19 August 2017

publication date

1 June 2008

1 reference

Expert Review of Gastroenterology & Hepatology

19 August 2017

published in

1 reference

19 August 2017

volume

2

1 reference

19 August 2017

issue

3

1 reference

19 August 2017

page(s)

299-314

1 reference

Immune dysfunction in inflammatory bowel disease

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Guidelines for the management of inflammatory bowel disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Preventing neoplastic progression in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Recent trends in the epidemiology of inflammatory bowel diseases: up or down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Mesalamine delivery systems: do they really make much difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Complications of biological therapy for inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Treatment of inflammatory bowel disease with corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Review article: practical management of inflammatory bowel disease patients taking immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Review article: aminosalicylates in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

The effect of food intake on the gastric emptying of gastric juice-resistant tablets and capsules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Systematic review: adherence issues in the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Determinants of life satisfaction in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Gastrointestinal transit and release of 5‐aminosalicylic acid from 153Sm‐labelled mesalazine pellets vs. tablets in male healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Combined scintigraphic and pharmacokinetic investigation of enteric‐coated mesalazine micropellets in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

The hepatitis C envelope 2 protein inhibits LFA-1-transduced protein kinase C signaling for T-lymphocyte migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Drug induced acute pancreatitis: incidence and severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.299

21 January 2018

Identifiers

DOI

10.1586/17474124.2.3.299

1 reference

19 August 2017

1 reference